CGTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CGTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cognition Therapeutics's Change In Other Working Capital for the quarter that ended in Sep. 2024 was $-0.38 Mil. It means Cognition Therapeutics's Other Working Capital declined by $0.38 Mil from Jun. 2024 to Sep. 2024 .
Cognition Therapeutics's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-1.84 Mil. It means Cognition Therapeutics's Other Working Capital declined by $1.84 Mil from Dec. 2022 to Dec. 2023 .
The historical data trend for Cognition Therapeutics's Change In Other Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cognition Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Change In Other Working Capital | -0.09 | 0.25 | 0.50 | 2.51 | -1.84 |
Cognition Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Change In Other Working Capital | Get a 7-Day Free Trial | -0.19 | -0.30 | -0.14 | -0.18 | -0.38 |
Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.
Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cognition Therapeutics's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Lisa Ricciardi | director, officer: CEO & President | C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
John Brendan Doyle | officer: Chief Financial Officer | C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494 |
Anthony Caggiano | officer: Chief Medical Officer | C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
Ellen B Richstone | director | C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886 |
Fletcher Aaron G.l. | director | 40 GUEST STREET, BOSTON MA 02135 |
Leslie W. Kreis | director, 10 percent owner | 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Bios Fund Iii, Lp | 10 percent owner | 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Bios Memory Spv Ii, Lp | 10 percent owner | 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
Bios Fund Iii Nt, Lp | 10 percent owner | 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Bios Equity Partners Ii, Lp | 10 percent owner | 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Bios Fund Iii Qp, Lp | 10 percent owner | 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Peggy Wallace | director | C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577 |
Bios Equity Partners Iii, Lp | 10 percent owner | 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
Bios Fund Ii Nt, Lp | 10 percent owner | 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
Bios Fund Ii Qp, Lp | 10 percent owner | 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
From GuruFocus
By Marketwired • 08-05-2024
By Marketwired • 08-08-2024
By Marketwired • 05-07-2024
By Marketwired • 10-23-2024
By Marketwired • 07-26-2024
By Marketwired • 10-22-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 11-25-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.